PCSS-B News

July 9, 2012

Press Release: FDA introduces new safety measures for extended-release and long-acting opioid medications

Questions and Answers: FDA approves a Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics

June 22, 2012

Acceptance of Naltrexone by Pregnant Women Enrolled in Comprehensive Drug Addiction Treatment: An Initial Survey By: Hendree E. Jones, PhD

June 14, 2012

Mental Illness in Teens Linked to Long-term Opioid Use, By: Joe Barber Jr, PhD

May 24, 2012

Cautious, Evidence-Based Opioid Prescribing: Physicians for Responsible Opioid Prescribing

May 15, 2012

Annals of Internal Medicine: Federal Plan for Prescriber Education on Opioids Misses Opportunities

May 10, 2012

Two New Resources to Curb Prescription Drug Abuse, By: Bret Stetka, MD; Elinore F. McCance-Katz, MD, PhD

April 18, 2012

PCSS-B Project Update

March 5, 2012

CESAR Report Warns of Emerging Epidemic of Buprenorphine Misuse

February 11, 2012

SAMHSA announces “An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People With Opioid Dependence,” Advisory, Volume 11, Issue 1. This Advisory provides an overview of extended-release injectable naltrexone (Vivitrol), a treatment for people with opioid dependence. The Advisory will help behavioral health professionals and medical healthcare providers:

Access information about extended-release injectable naltrexone.
Compare extended-release injectable naltrexone’s features with those of other medication-assistance treatment options (e.g., methadone and buprenorphine).
Consider clinical strategies in selecting, initiating, and administering treatment.
The Advisory is a bulletin that provides behavioral health providers and others with information on emerging issues and hot topics that have immediate consequences for those in the behavioral health field.
“An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People With Opioid Dependence,” Advisory, Volume 11, Issue 1 (SMA) 12-4682

February 6, 2012

Vermont Treatment Guidelines Regarding Treatment of Opioid Dependence During Pregnancy

Prior to 2012

Did You Give Up Your Waiver Because You Weren't Ready to Prescribe? Interested in Getting Your Waiver Reinstated?

How to Prepare for a Visit from the Drug Enforcement Administration (DEA) Regarding Buprenorphine Prescribing.


Copyright © 2013 PCSS-B   |  Disclaimer – Any information/materials that is provided/obtained on PCSS-B should not be construed as medical advice.